Healio2d
FDA grants brensocatib priority review for bronchiectasis
The FDA has granted priority review to brensocatib to treat patients with non-cystic fibrosis bronchiectasis, according to a ...
pharmaphorum2d
FDA starts review of first bronchiectasis drug candidate
DPP1 inhibitor brensocatib has been submitted for approval by the FDA for non-cystic fibrosis bronchiectasis based on the results of the ASPEN trial, which showed that the drug cut the number of ...
Monthly Prescribing Reference7d
Brensocatib Gets Priority Review for Non-Cystic Fibrosis Bronchiectasis
A Prescription Drug User Fee Act target date of August 12, 2025 has been set for the application. The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application ...
MarketWatch6d
Insmed Gets Speedy FDA Review of Brensocatib for Bronchiectasis
The Bridgewater, N.J., biopharmaceutical company said brensocatib has the potential to become the first and only approved treatment for non-cystic fibrosis bronchiectasis, which causes the lungs ...
Medscape8d
Diagnosis of Allergic Bronchopulmonary Aspergillosis: A Case-Based Approach
Allergic bronchopulmonary aspergillosis is a pulmonary disease occurring in patients with asthma or cystic ... B: Bronchiectasis; CPF: Chronic pleuropulmonary fibrosis; HAM: High attenuation ...
Insmed Stock Surges on Trial Win for Lung-Condition Drug. ‘We Hit the Mark,’ CEO Says.
While bronchiectasis occurs in patients with cystic fibrosis, Insmed tested brensocatib in patients with the condition who ...